Clarity’s theranostic prostate cancer trial advances to cohort 2
Sydney, Australia 24 May 2023 Highlights Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq. No dose limiting toxicities (DLTs) have been reported in cohort 1. The Safety Review Committee (SRC) has recommended…